Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-09-16

AUTHORS

Will Dunlop, Marjolijn van Keep, Peter Elroy, Ignacio Diaz Perez, Mario J. N. M. Ouwens, Tina Sarbajna, Yiduo Zhang, Alastair Greystoke

ABSTRACT

BackgroundIn the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK’s National Institute for Health and Care Excellence (NICE) included a cost-effectiveness analysis based on an early data readout from PACIFIC [March 2018 data cut-off (DCO); median follow-up duration 25.2 months; range 0.2–43.1]. Uncertainties regarding long-term survival outcomes with durvalumab led to some challenges in estimating the cost effectiveness of this therapy.ObjectiveHere, we validate the survival extrapolations used in the original company base-case analysis by benchmarking them against updated survival data from the 4-year follow-up analysis of PACIFIC (i.e. approximately 4 years after the last patient was randomised; March 2020 DCO; median follow-up duration 34.2 months; range 0.2–64.9). Moreover, we update the original analysis with these more mature survival data to examine the consistency of key economic outputs with the original analysis.MethodsThe original analysis used a semi-Markov (state-transition) approach and was based on patients whose tumours expressed programmed cell death-ligand 1 on ≥ 1% of cells (to reflect the European licence for durvalumab). We benchmarked the survival extrapolations used in the original company base-case analysis against survival data from the 4-year follow-up of PACIFIC and updated the cost-effectiveness analysis with these more mature survival data. Early deaths avoided by the adoption of durvalumab into the UK Cancer Drugs Fund (CDF) in March 2019 were estimated using the 4-year follow-up survival data and an assumed uptake of 125 patients/year (lower estimate) and 367 patients/year (higher estimate).ResultsThe original company base-case analysis had a good visual fit with the observed overall survival (OS) distribution for the durvalumab arm and accurately predicted the 48-month OS rate (predicted 55%; observed 55%); by comparison, the fit was less precise for the placebo arm, for which the analysis underestimated the 48-month OS rate (predicted 32%; observed 38%). In the updated company base-case analysis, durvalumab yielded 2.51 incremental quality-adjusted life-years (QALYs) (− 0.43 vs. the original company base-case analysis), corresponding to an incremental cost-effectiveness ratio of £22,665/QALY (+£3298 vs. the original analysis), which falls within the upper bound of NICE’s willingness-to-pay threshold (£30,000/QALY gained). We estimate that between 31 and 91 early patient deaths may have been avoided by the adoption of durvalumab into the CDF.ConclusionsThese findings reinforce the patient benefit observed with durvalumab in unresectable stage III NSCLC, support the routine use and cost effectiveness of this therapy, and demonstrate how appropriate modelling can inform the early adoption of therapies by payers to achieve patient benefit. More... »

PAGES

1-12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-021-00301-7

DOI

http://dx.doi.org/10.1007/s41669-021-00301-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1141165882

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34532842


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dunlop", 
        "givenName": "Will", 
        "id": "sg:person.011256600425.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011256600425.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BresMed Netherlands, Utrecht, The Netherlands", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "BresMed Netherlands, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Keep", 
        "givenName": "Marjolijn", 
        "id": "sg:person.01215062721.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BresMed Netherlands, Utrecht, The Netherlands", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "BresMed Netherlands, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elroy", 
        "givenName": "Peter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gaithersburg, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perez", 
        "givenName": "Ignacio Diaz", 
        "id": "sg:person.013735223161.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013735223161.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gothenburg, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "AstraZeneca, Gothenburg, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ouwens", 
        "givenName": "Mario J. N. M.", 
        "id": "sg:person.0703577301.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703577301.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sarbajna", 
        "givenName": "Tina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Gaithersburg, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Yiduo", 
        "id": "sg:person.013547704542.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013547704542.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK", 
          "id": "http://www.grid.ac/institutes/grid.420004.2", 
          "name": [
            "Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greystoke", 
        "givenName": "Alastair", 
        "id": "sg:person.0773547677.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773547677.71"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-019-1249-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111831523", 
          "https://doi.org/10.1007/s12032-019-1249-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-020-06734-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1126156423", 
          "https://doi.org/10.1186/s12885-020-06734-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-019-00845-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122679174", 
          "https://doi.org/10.1007/s40273-019-00845-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-09-16", 
    "datePublishedReg": "2021-09-16", 
    "description": "BackgroundIn the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK\u2019s National Institute for Health and Care Excellence (NICE) included a cost-effectiveness analysis based on an early data readout from PACIFIC [March 2018 data cut-off (DCO); median follow-up duration 25.2 months; range 0.2\u201343.1]. Uncertainties regarding long-term survival outcomes with durvalumab led to some challenges in estimating the cost effectiveness of this therapy.ObjectiveHere, we validate the survival extrapolations used in the original company base-case analysis by benchmarking them against updated survival data from the 4-year follow-up analysis of PACIFIC (i.e. approximately 4 years after the last patient was randomised; March 2020 DCO; median follow-up duration 34.2\u00a0months; range 0.2\u201364.9). Moreover, we update the original analysis with these more mature survival data to examine the consistency of key economic outputs with the original analysis.MethodsThe original analysis used a semi-Markov (state-transition) approach and was based on patients whose tumours expressed programmed cell death-ligand 1 on \u2265\u00a01% of cells (to reflect the European licence for durvalumab). We benchmarked the survival extrapolations used in the original company base-case analysis against survival data from the 4-year follow-up of PACIFIC and updated the cost-effectiveness analysis with these more mature survival data. Early deaths avoided by the adoption of durvalumab into the UK Cancer Drugs Fund (CDF) in March 2019 were estimated using the 4-year follow-up survival data and an assumed uptake of 125 patients/year (lower estimate) and 367 patients/year (higher estimate).ResultsThe original company base-case analysis had a good visual fit with the observed overall survival (OS) distribution for the durvalumab arm and accurately predicted the 48-month OS rate (predicted 55%; observed 55%); by comparison, the fit was less precise for the placebo arm, for which the analysis underestimated the 48-month OS rate (predicted 32%; observed 38%). In the updated company base-case analysis, durvalumab yielded 2.51 incremental quality-adjusted life-years (QALYs) (\u2212\u00a00.43 vs. the original company base-case analysis), corresponding to an incremental cost-effectiveness ratio of \u00a322,665/QALY (+\u00a33298 vs. the original analysis), which falls within the upper bound of NICE\u2019s willingness-to-pay threshold (\u00a330,000/QALY gained). We estimate that between 31 and 91 early patient deaths may have been avoided by the adoption of durvalumab into the CDF.ConclusionsThese findings reinforce the patient benefit observed with durvalumab in unresectable stage III NSCLC, support the routine use and cost effectiveness of this therapy, and demonstrate how appropriate modelling can inform the early adoption of therapies by payers to achieve patient benefit.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41669-021-00301-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "base-case analysis", 
      "unresectable stage III NSCLC", 
      "stage III NSCLC", 
      "Cancer Drugs Fund", 
      "patient/year", 
      "mature survival data", 
      "cost-effectiveness analysis", 
      "OS rates", 
      "survival data", 
      "patient benefit", 
      "long-term survival outcomes", 
      "platinum-based concurrent chemoradiotherapy", 
      "unresectable stage III", 
      "incremental cost-effectiveness ratio", 
      "UK healthcare perspective", 
      "cell lung cancer", 
      "overall survival distribution", 
      "UK National Institute", 
      "National Institute", 
      "cost-effectiveness ratio", 
      "survival extrapolation", 
      "early patient death", 
      "cost effectiveness", 
      "NICE willingness", 
      "survival update", 
      "concurrent chemoradiotherapy", 
      "placebo arm", 
      "survival outcomes", 
      "lung cancer", 
      "patient death", 
      "durvalumab", 
      "Care Excellence", 
      "early death", 
      "stage III", 
      "pay thresholds", 
      "healthcare perspective", 
      "routine use", 
      "ConclusionsThese findings", 
      "Drugs Fund", 
      "therapy", 
      "NSCLC", 
      "patients", 
      "follow", 
      "death", 
      "survival distributions", 
      "chemoradiotherapy", 
      "placebo", 
      "cells", 
      "arm", 
      "tumors", 
      "years", 
      "cancer", 
      "QALY", 
      "disease", 
      "survival", 
      "outcomes", 
      "payers", 
      "BackgroundIn", 
      "health", 
      "benefits", 
      "rate", 
      "data", 
      "findings", 
      "early adoption", 
      "uptake", 
      "best visual fit", 
      "effectiveness", 
      "analysis", 
      "Pacific Studies", 
      "original analysis", 
      "study", 
      "Institute", 
      "willingness", 
      "update", 
      "use", 
      "threshold", 
      "appraisal", 
      "visual fit", 
      "ratio", 
      "comparison", 
      "validation", 
      "challenges", 
      "excellence", 
      "consistency", 
      "adoption", 
      "extrapolation", 
      "output", 
      "fit", 
      "approach", 
      "perspective", 
      "readout", 
      "distribution", 
      "funds", 
      "uncertainty", 
      "model validation", 
      "appropriate modelling", 
      "semi-Markov approach", 
      "modelling", 
      "Pacific", 
      "economic output", 
      "data readout", 
      "phase III PACIFIC study", 
      "III PACIFIC study", 
      "early data readout", 
      "original company base-case analysis", 
      "company base-case analysis", 
      "analysis of PACIFIC", 
      "key economic outputs", 
      "MethodsThe original analysis", 
      "adoption of durvalumab", 
      "UK Cancer Drugs Fund", 
      "observed overall survival (OS) distribution", 
      "durvalumab arm", 
      "III NSCLC"
    ], 
    "name": "Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective", 
    "pagination": "1-12", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1141165882"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-021-00301-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34532842"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-021-00301-7", 
      "https://app.dimensions.ai/details/publication/pub.1141165882"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_883.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41669-021-00301-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00301-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00301-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00301-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00301-7'


 

This table displays all metadata directly associated to this object as RDF triples.

240 TRIPLES      22 PREDICATES      141 URIs      130 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-021-00301-7 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N50861502e48a42c2a279eab042f62e54
4 schema:citation sg:pub.10.1007/s12032-019-1249-1
5 sg:pub.10.1007/s40273-019-00845-x
6 sg:pub.10.1186/s12885-020-06734-3
7 schema:datePublished 2021-09-16
8 schema:datePublishedReg 2021-09-16
9 schema:description BackgroundIn the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK’s National Institute for Health and Care Excellence (NICE) included a cost-effectiveness analysis based on an early data readout from PACIFIC [March 2018 data cut-off (DCO); median follow-up duration 25.2 months; range 0.2–43.1]. Uncertainties regarding long-term survival outcomes with durvalumab led to some challenges in estimating the cost effectiveness of this therapy.ObjectiveHere, we validate the survival extrapolations used in the original company base-case analysis by benchmarking them against updated survival data from the 4-year follow-up analysis of PACIFIC (i.e. approximately 4 years after the last patient was randomised; March 2020 DCO; median follow-up duration 34.2 months; range 0.2–64.9). Moreover, we update the original analysis with these more mature survival data to examine the consistency of key economic outputs with the original analysis.MethodsThe original analysis used a semi-Markov (state-transition) approach and was based on patients whose tumours expressed programmed cell death-ligand 1 on ≥ 1% of cells (to reflect the European licence for durvalumab). We benchmarked the survival extrapolations used in the original company base-case analysis against survival data from the 4-year follow-up of PACIFIC and updated the cost-effectiveness analysis with these more mature survival data. Early deaths avoided by the adoption of durvalumab into the UK Cancer Drugs Fund (CDF) in March 2019 were estimated using the 4-year follow-up survival data and an assumed uptake of 125 patients/year (lower estimate) and 367 patients/year (higher estimate).ResultsThe original company base-case analysis had a good visual fit with the observed overall survival (OS) distribution for the durvalumab arm and accurately predicted the 48-month OS rate (predicted 55%; observed 55%); by comparison, the fit was less precise for the placebo arm, for which the analysis underestimated the 48-month OS rate (predicted 32%; observed 38%). In the updated company base-case analysis, durvalumab yielded 2.51 incremental quality-adjusted life-years (QALYs) (− 0.43 vs. the original company base-case analysis), corresponding to an incremental cost-effectiveness ratio of £22,665/QALY (+£3298 vs. the original analysis), which falls within the upper bound of NICE’s willingness-to-pay threshold (£30,000/QALY gained). We estimate that between 31 and 91 early patient deaths may have been avoided by the adoption of durvalumab into the CDF.ConclusionsThese findings reinforce the patient benefit observed with durvalumab in unresectable stage III NSCLC, support the routine use and cost effectiveness of this therapy, and demonstrate how appropriate modelling can inform the early adoption of therapies by payers to achieve patient benefit.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf sg:journal.1284515
14 schema:keywords BackgroundIn
15 Cancer Drugs Fund
16 Care Excellence
17 ConclusionsThese findings
18 Drugs Fund
19 III NSCLC
20 III PACIFIC study
21 Institute
22 MethodsThe original analysis
23 NICE willingness
24 NSCLC
25 National Institute
26 OS rates
27 Pacific
28 Pacific Studies
29 QALY
30 UK Cancer Drugs Fund
31 UK National Institute
32 UK healthcare perspective
33 adoption
34 adoption of durvalumab
35 analysis
36 analysis of PACIFIC
37 appraisal
38 approach
39 appropriate modelling
40 arm
41 base-case analysis
42 benefits
43 best visual fit
44 cancer
45 cell lung cancer
46 cells
47 challenges
48 chemoradiotherapy
49 company base-case analysis
50 comparison
51 concurrent chemoradiotherapy
52 consistency
53 cost effectiveness
54 cost-effectiveness analysis
55 cost-effectiveness ratio
56 data
57 data readout
58 death
59 disease
60 distribution
61 durvalumab
62 durvalumab arm
63 early adoption
64 early data readout
65 early death
66 early patient death
67 economic output
68 effectiveness
69 excellence
70 extrapolation
71 findings
72 fit
73 follow
74 funds
75 health
76 healthcare perspective
77 incremental cost-effectiveness ratio
78 key economic outputs
79 long-term survival outcomes
80 lung cancer
81 mature survival data
82 model validation
83 modelling
84 observed overall survival (OS) distribution
85 original analysis
86 original company base-case analysis
87 outcomes
88 output
89 overall survival distribution
90 patient benefit
91 patient death
92 patient/year
93 patients
94 pay thresholds
95 payers
96 perspective
97 phase III PACIFIC study
98 placebo
99 placebo arm
100 platinum-based concurrent chemoradiotherapy
101 rate
102 ratio
103 readout
104 routine use
105 semi-Markov approach
106 stage III
107 stage III NSCLC
108 study
109 survival
110 survival data
111 survival distributions
112 survival extrapolation
113 survival outcomes
114 survival update
115 therapy
116 threshold
117 tumors
118 uncertainty
119 unresectable stage III
120 unresectable stage III NSCLC
121 update
122 uptake
123 use
124 validation
125 visual fit
126 willingness
127 years
128 schema:name Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
129 schema:pagination 1-12
130 schema:productId Nbc878c30863f4ba89563c339ad7387c5
131 Nc266b5f88e804e219b92da6e23eb049b
132 Nd4fd857823044ebc982906d36076e404
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141165882
134 https://doi.org/10.1007/s41669-021-00301-7
135 schema:sdDatePublished 2022-01-01T18:57
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher Na2cbec878170413db36d7c66d6fb2e36
138 schema:url https://doi.org/10.1007/s41669-021-00301-7
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N001c0911b14a4f21830464c01be1df17 schema:affiliation grid-institutes:None
143 schema:familyName Sarbajna
144 schema:givenName Tina
145 rdf:type schema:Person
146 N1ec310fd53f045dba6d5ad814357938e rdf:first N6cd4250cb37b475a8e35473554684701
147 rdf:rest Nb7c76a92fb65457fae4d5ca6079c132b
148 N2343c3708c2d409c85df368703a68e11 rdf:first sg:person.013547704542.95
149 rdf:rest Nca7ee4a77d4848fd83cb61bfc622177e
150 N473f67b29c884b3caa8d0481bbf54596 rdf:first N001c0911b14a4f21830464c01be1df17
151 rdf:rest N2343c3708c2d409c85df368703a68e11
152 N50861502e48a42c2a279eab042f62e54 rdf:first sg:person.011256600425.32
153 rdf:rest Nbdce308bc5874e8abc4aa4e50f36737a
154 N6cd4250cb37b475a8e35473554684701 schema:affiliation grid-institutes:None
155 schema:familyName Elroy
156 schema:givenName Peter
157 rdf:type schema:Person
158 N715ea9facb7945fdb37e0633cdcf7662 rdf:first sg:person.0703577301.41
159 rdf:rest N473f67b29c884b3caa8d0481bbf54596
160 Na2cbec878170413db36d7c66d6fb2e36 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nb7c76a92fb65457fae4d5ca6079c132b rdf:first sg:person.013735223161.74
163 rdf:rest N715ea9facb7945fdb37e0633cdcf7662
164 Nbc878c30863f4ba89563c339ad7387c5 schema:name pubmed_id
165 schema:value 34532842
166 rdf:type schema:PropertyValue
167 Nbdce308bc5874e8abc4aa4e50f36737a rdf:first sg:person.01215062721.00
168 rdf:rest N1ec310fd53f045dba6d5ad814357938e
169 Nc266b5f88e804e219b92da6e23eb049b schema:name dimensions_id
170 schema:value pub.1141165882
171 rdf:type schema:PropertyValue
172 Nca7ee4a77d4848fd83cb61bfc622177e rdf:first sg:person.0773547677.71
173 rdf:rest rdf:nil
174 Nd4fd857823044ebc982906d36076e404 schema:name doi
175 schema:value 10.1007/s41669-021-00301-7
176 rdf:type schema:PropertyValue
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
181 schema:name Public Health and Health Services
182 rdf:type schema:DefinedTerm
183 sg:journal.1284515 schema:issn 2509-4254
184 2509-4262
185 schema:name PharmacoEconomics - Open
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.011256600425.32 schema:affiliation grid-institutes:None
189 schema:familyName Dunlop
190 schema:givenName Will
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011256600425.32
192 rdf:type schema:Person
193 sg:person.01215062721.00 schema:affiliation grid-institutes:None
194 schema:familyName van Keep
195 schema:givenName Marjolijn
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00
197 rdf:type schema:Person
198 sg:person.013547704542.95 schema:affiliation grid-institutes:grid.418152.b
199 schema:familyName Zhang
200 schema:givenName Yiduo
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013547704542.95
202 rdf:type schema:Person
203 sg:person.013735223161.74 schema:affiliation grid-institutes:grid.418152.b
204 schema:familyName Perez
205 schema:givenName Ignacio Diaz
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013735223161.74
207 rdf:type schema:Person
208 sg:person.0703577301.41 schema:affiliation grid-institutes:grid.418151.8
209 schema:familyName Ouwens
210 schema:givenName Mario J. N. M.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703577301.41
212 rdf:type schema:Person
213 sg:person.0773547677.71 schema:affiliation grid-institutes:grid.420004.2
214 schema:familyName Greystoke
215 schema:givenName Alastair
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773547677.71
217 rdf:type schema:Person
218 sg:pub.10.1007/s12032-019-1249-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111831523
219 https://doi.org/10.1007/s12032-019-1249-1
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s40273-019-00845-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1122679174
222 https://doi.org/10.1007/s40273-019-00845-x
223 rdf:type schema:CreativeWork
224 sg:pub.10.1186/s12885-020-06734-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126156423
225 https://doi.org/10.1186/s12885-020-06734-3
226 rdf:type schema:CreativeWork
227 grid-institutes:None schema:alternateName AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK
228 BresMed Netherlands, Utrecht, The Netherlands
229 schema:name AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0AA, Cambridge, UK
230 BresMed Netherlands, Utrecht, The Netherlands
231 rdf:type schema:Organization
232 grid-institutes:grid.418151.8 schema:alternateName AstraZeneca, Gothenburg, Sweden
233 schema:name AstraZeneca, Gothenburg, Sweden
234 rdf:type schema:Organization
235 grid-institutes:grid.418152.b schema:alternateName AstraZeneca, Gaithersburg, MD, USA
236 schema:name AstraZeneca, Gaithersburg, MD, USA
237 rdf:type schema:Organization
238 grid-institutes:grid.420004.2 schema:alternateName Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
239 schema:name Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
240 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...